[

FMISO RANO glioblastoma pembrolizumab pseudoprogression

Journal

Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528

Informations de publication

Date de publication:
May 2022
Historique:
entrez: 23 5 2022
pubmed: 24 5 2022
medline: 24 5 2022
Statut: epublish

Résumé

Response assessment after immunotherapy remains a major challenge in glioblastoma due to an expected increased incidence of pseudoprogression. Gadolinium-enhanced magnetic resonance imaging (MRI) is the standard for monitoring therapeutic response, however, is markedly limited in characterizing pseudoprogression. Given that hypoxia is an important defining feature of glioblastoma regrowth, we hypothesized that [

Identifiants

pubmed: 35601969
doi: 10.1093/nop/npac021
pii: npac021
pmc: PMC9113243
doi:

Types de publication

Case Reports

Langues

eng

Pagination

246-250

Subventions

Organisme : NCI NIH HHS
ID : K08 CA237809
Pays : United States
Organisme : NCI NIH HHS
ID : L30 CA220897
Pays : United States

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Références

Lancet Oncol. 2015 Nov;16(15):e534-e542
pubmed: 26545842
PLoS One. 2018 Jun 14;13(6):e0198548
pubmed: 29902200
Tomography. 2020 Mar;6(1):14-22
pubmed: 32280746
J Clin Oncol. 2017 Jul 20;35(21):2439-2449
pubmed: 28640707
Int J Rad Appl Instrum A. 1986;37(7):599-605
pubmed: 3021662
Biomedicines. 2016 Oct 31;4(4):
pubmed: 28536391
Eur Radiol. 2017 Oct;27(10):4129-4144
pubmed: 28332014
Neuro Oncol. 2019 Mar 18;21(4):517-526
pubmed: 30277536
Eur Radiol. 2018 Jun;28(6):2628-2638
pubmed: 29374321
J Neuropathol Exp Neurol. 2006 Jun;65(6):529-39
pubmed: 16783163
Sci Rep. 2021 Apr 7;11(1):7632
pubmed: 33828310
Neurotherapeutics. 2017 Apr;14(2):307-320
pubmed: 28108885
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
World Neurosurg. 2020 Dec;144:e100-e109
pubmed: 32777397
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Radiat Res. 1990 Jun;122(3):301-8
pubmed: 2356284
Neuroimage Clin. 2016 Dec 18;13:386-394
pubmed: 28116231
J Clin Oncol. 1990 Jul;8(7):1277-80
pubmed: 2358840
Nat Med. 2019 Mar;25(3):477-486
pubmed: 30742122
CNS Oncol. 2014 Nov;3(6):389-400
pubmed: 25438810
BMC Clin Pathol. 2012 Feb 28;12:4
pubmed: 22373026

Auteurs

Ramon F Barajas (RF)

Department of Radiology, Neuroradiology Section, Oregon Health & Science University, Portland Oregon, USA.
Knight Cancer Institute Translational Oncology Program, Oregon Health & Science University, Portland, Oregon, USA.

Prakash Ambady (P)

Neuro-Oncology and Blood-Brain Barrier Program, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.

Jeanne Link (J)

Center for Radiochemistry Research, Oregon Health & Science University, Portland, Oregon, USA.

Kenneth A Krohn (KA)

Center for Radiochemistry Research, Oregon Health & Science University, Portland, Oregon, USA.

Ahmed Raslan (A)

Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA.

Nadine Mallak (N)

Advanced Imaging Research Center, Oregon Health & Science University, Portland Oregon, USA.

Randy Woltjer (R)

Department of Pathology, Oregon Health & Science University, Portland, Oregon, USA.

Leslie Muldoon (L)

Neuro-Oncology and Blood-Brain Barrier Program, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.

Edward A Neuwelt (EA)

Neuro-Oncology and Blood-Brain Barrier Program, Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA.
Department of Neurological Surgery, Oregon Health & Science University, Portland, Oregon, USA.
Office of Research and Development, Portland Veterans Affairs Medical Center, Portland, Oregon, USA.

Classifications MeSH